3.1. Entry Submission
By submitting an Entry, the Participant accepts these Terms.
Entries must be submitted via the Competition website and must
include all information required, including but not limited to:
- The idea or concept and how it can improve skeletal muscle
health, muscle insulin sensitivity, enhance muscle mass or function,
or develop novel muscle targeting concepts
- Maturity level
– e.g. is there any existing data that support the idea/concept,
what IP rights exist
- High level project plan for testing
the idea/concept within the Co-creation Greenhouse period, including
timelines and key milestones, and main challenges that remain to be
- Suggested plan for how the Participant and Novo
Nordisk could use the Co-creation Greenhouse format to progress the
idea/concept, e.g. reach proof concept and/or perform a feasibility
- Description of you as Participant (or, if
applicable the Participant Team), number of employees, funding
status (including total amount of funding received at the time of
the application), address, phone number and email address
- Any relevant supporting information (e.g., non-confidential
slide deck, publication, patents, posters, CVs) can be submitted as
- Confirmation that the Participant has read and
understood the terms and conditions.
Entries may be submitted at any time during the Open Call Period. An
Entry is not complete unless and until the Entry criteria above are
properly followed. Submitted entries will not be returned.
Entries will be considered non-confidential. By submitting an Entry,
Participant acknowledges and agrees that the Entry will not be treated
as confidential. Participant is advised, before submitting an Entry,
to consult a lawyer or patent attorney as to the desirability of
seeking patents or other protection for the Entry.
By submitting an Entry, Participant warrants and represents that:
i. The Entry is the original work of Participant;
ii. Participant and, if applicable, Participant Team, has consented
to the submission and use of the Entry in the Competition;
iii. The Entry does not contain any copyrighted material not owned
by Participant or, if applicable, Participant Team and, to the best of
Participant’s knowledge, does not infringe the rights of any third
party, including but not limited to rights of publicity or privacy,
moral rights, or any other property rights;
iv. Participant has the right to present the Entry and to
participate in the Competition and there are no claims, judgments or
settlements against or owed by Participant relating to the Entry or
any information contained therein;
v. The Entry only contains names/likeness/identifying elements of
persons for the use of which these persons have given their prior
written consent to Participant.
In the Entry, Participant must disclose whether:
a) Participant has any currently active formal partnerships
with other pharmaceutical companies;
b) Participant is a Health Care Professional (HCP).
Participant’s submission of the Entry is at its own responsibility
and risk. Novo Nordisk shall not be liable for loss of data or illegal
intrusion into its systems by third parties.
3.2 Review of Entries
The entries will be judged and scored by a review panel chosen by
Novo Nordisk (“Review Panel”).
The Review Panel will rank the entries based on the following
1. Disease link (not relevant for ideas/concepts related
to muscle targeting concepts). Is there a clear biological
hypothesis and link to skeletal muscle health, and/or insulin
resistance/type 2 diabetes.
2. Project plan. To which extent can the
hypothesis/idea/concept be experimentally tested and has a “killer
experiment” (to test the hypothesis and increase the confidence in the
link to skeletal muscle health and type 2 diabetes) been defined that
could be finalized within the Cocreation Greenhouse period?
3. Innovation height. To which extent does the
idea/concept differ from existing drugs/solutions on the market?
Novo Nordisk reserves the right to assess the entries in its sole
discretion, which may include interviews or discussions with certain Participants.
3.3 Selection of Participants
As many as up to ten (10) of the entries ranked highest by the
Review Panel will be selected to progress (referred to as “Selected
Participants”), subject to verification and compliance with these
Terms. The Selected Participants will be notified by the email address
they provided by October 5, 2023.
If an email notification is returned as undeliverable, or if
Selected Participants do not respond within the required number of
days specified by Novo Nordisk, or if any information submitted by
Participant is found in non-compliance with the Terms, raises
significant concern to Novo Nordisk, or if potential Selected
Participants decide to decline selection as Selected Participants for
any reason, Novo Nordisk shall have no further obligations to such
Selected Participants and a place as Selected Participants may instead
be awarded to a runner-up Selected Participant, time-permitting and at
Novo Nordisk’s sole discretion.
The Selected Participants may receive questions or other feedback
from Novo Nordisk after being selected as Selected Participants.
3.4. Selection of Winners
On October 24, 2023, the Selected Participants will present their
final proposed research project to the Review Panel in a review
meeting where Novo Nordisk will judge the Selected Participants’ final
project. Novo Nordisk can select up to three (3) winners of the
Co-creation Greenhouse (the “Winners”). Novo Nordisk may elect
not to select any Winners.
As stated above in “Eligibility”, to be eligible to win the
Co-creation Greenhouse, the Winner must be a duly incorporated legal
entity with a US federal tax number.
The Co-creation Greenhouse Winner will receive: (i) a research grant
of 50,000 USD, (ii) an offer of mentoring from a Novo Nordisk
scientist for up to three (3) hours per week over a six (6) months
period and (iii) in-kind support, as deemed necessary by Novo Nordisk,
for achieving the agreed research goals.
The research grant of 50,000 USD will be paid in one (1) installment
at the beginning of the research project . The research grant may only
be spent as agreed with Novo Nordisk in the research project plan. The
research grant may not be spent on travel costs.
The Winner will be notified via the email address they provided by
November 6th, 2023.
If an email notification is returned as undeliverable, if a Winner
does not respond within the required number of days specified by Novo
Nordisk, if any information submitted by Participant is found in
non-compliance with the Terms or raises significant concern to Novo
Nordisk in Novo Nordisk’s sole discretion, or if a Winner decides to
decline the prize for any reason, Novo Nordisk shall have no further
obligations to such Winner and the applicable prize will be forfeited
and may be awarded to a runner-up Winner, time-permitting and at Novo
Nordisk’s sole discretion.
If, once selected as a Winner, a Selected Participant is of the
opinion that their solution cannot be further discussed or developed
without the disclosure of any confidential or proprietary information,
Novo Nordisk may decide to enter into a confidentiality agreement with
Participant to ensure that the mutual interests are well protected.
The Co-creation Greenhouse is non-transferable and substitutions or
cash redemptions will not be allowed. Except where prohibited by law,
all tax liabilities are the responsibility of the Co-creation
Greenhouse Winner. Novo Nordisk will not be responsible for any tax
deductions which may be necessary. Participant acknowledges that
he/she will not be entitled to any additional payment by reason of any
award(s) being subject to any tax, levy, or other charge in any jurisdiction.
The Co-creation Greenhouse Winner is responsible for any additional
costs and expenses associated with the acceptance and/or use of the
Co-creation Greenhouse. All details of the prize not specified in
these Terms shall be determined by Novo Nordisk in its sole discretion.